India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

NATCO Pharma Limited: Record Year Performance Overshadowed by Cautious FY26 Outlook

Natco Pharma (NTCPH IN): Getting Ready for the Next Moonshot

Event Driven: Natco Pharma’s Strategic Acquisition of Adcock Ingram

The Beat Ideas: Blue Jet Healthcare- Rising CDMO Player

The Beat Ideas: Natco Pharma, The Cheapest Pharma Stock

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>There will be significant drop in revenue in FY26 due to the loss of exclusivity of the key product, but company is looking for acquisition &amp; doing R&amp;D.  </li>
<li>Natco is focusing on launching the oral version of Semaglutide in the Indian market and is awaiting regulatory approvals for clinical trials.</li>
<li>Primary reason of fall in revenue was the absence of sales from a key product.</li>
</ul>


There will be significant drop in revenue in FY26 due to the loss of exclusivity of the key product, but company is looking for acquisition &amp; doing R&amp;D.  
Natco is focusing on launching the oral version of Semaglutide in the Indian market and is awaiting regulatory approvals for clinical trials.
Primary reason of fall in revenue was the absence of sales from a key product.


Natco Pharma Q3 FY25 Earnings Analysis: 20% Lower Circuit Post Result